Raptor's PROCYSBI(TM) Receives U.S. Orphan Drug Exclusivity
June 25, 2013 at 16:07 PM EDT
Raptor Pharmaceutical Corp. (Nasdaq: RPTP ) today announced that the Office of Orphan Product Development at the Food and Drug Administration (FDA) granted Raptor orphan drug exclusivity for PROCYSBI™ (cysteamine bitartrate) delayed-release capsules for the management of nephropathic cystinosis patients age six and older. The exclusivity period began on
